ArticleThe Pan African medical journal2024
[Incidence and determinants of viral load rebound in people receiving multi-month dispensing of antiretroviral therapy at the Regional Annex Hospital of Dschang from 2018-2023].
Article in The Pan African medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: in Cameroon, multi-month dispensing (MMD) of antiretrovirals (ARVs) was introduced to improve treatment adherence among people living with HIV (PLHIV). However, this strategy has limitations that may lead to viral load rebound. The purpose of this study is to assess the incidence and factors associated with viral rebound in PLHIV receiving MMD at the Dschang Regional Annex Hospital between 2018 and 2023. Methods: we conducted a retrospective cohort study comparing the incidence of viral rebound (increase of over 100 copies/mL after suppression) and its determinants in patients on MMD versus those on monthly dispensing (MD) from January 2018 to December 2023. Data were collected from patients´ medical records using a standardized data collection sheet. Descriptive statistics were followed by bivariate and multivariate analyses to identify factors associated with viral rebound, with a significance threshold of p<0.05. Results: a total of 519 patients (438 on MMD and 81 on MD) were included. The incidence of viral rebound was 18.8% among patients on MMD compared to 37.8% among those on MD. The male-to-female ratio was 0.53, with the majority of patients aged 30 to 45 years. MMD coverage decreased from 76% in 2018 to 51.02% in 2023. Factors significantly associated with viral rebound included dispensing type (p=0.001), treatment interruption (p=0.001), age group 30-45 years (p=0.001) and tobacco use (p=0.008). Conclusion: the incidence of viral rebound is higher among patients on MD. Improving the management of PLHIV and promoting healthier lifestyle choices are essential to prevent long-term treatment failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.